

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT DENGUE

The purpose of this resolution is to add a vaccine for the prevention of Dengue¹ to the VFC program.

Eligible Groups

- Children aged 9-16 years of age with laboratory confirmation of previous dengue infection and living in endemic areas (i.e., Puerto Rico, American Samoa, and the US Virgin Islands).
 - This VFC resolution will be updated, as necessary, if dengue-endemic areas in the US or its territories change.

Recommended Vaccination Schedule and Intervals

- Three doses administered 6 months apart at 0, 6, and 12 months

Recommended dosage

Refer to product package inserts.

Contraindications and Precautions

Contraindications and Precautions can be found in the package inserts available at <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states>

- ¹. As of September 1, 2026, Dengue vaccine is no longer available for administration in the United States.

[If an ACIP recommendation or notice regarding Dengue vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: June 24, 2021

This document can be found on the CDC website at:
<https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html>